Blue Trust Inc. Lowers Holdings in argenx SE (NASDAQ:ARGX)

Blue Trust Inc. lessened its stake in argenx SE (NASDAQ:ARGX) by 55.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 165 shares of the company’s stock after selling 205 shares during the quarter. Blue Trust Inc.’s holdings in argenx were worth $101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of ARGX. FMR LLC raised its position in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of argenx in the 3rd quarter worth about $88,339,000. Allspring Global Investments Holdings LLC raised its position in shares of argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after purchasing an additional 143,834 shares during the last quarter. Jennison Associates LLC raised its position in shares of argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after purchasing an additional 64,183 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after purchasing an additional 55,617 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. boosted their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. HC Wainwright reissued a “buy” rating and issued a $717.00 target price (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Finally, Truist Financial reissued a “buy” rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Trading Down 0.5 %

Shares of NASDAQ:ARGX opened at $644.48 on Friday. The stock has a 50 day moving average of $643.06 and a 200 day moving average of $587.26. The company has a market cap of $39.16 billion, a PE ratio of -732.36 and a beta of 0.58. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.